Skip to main content

Table 6 Events at 6 months by antithrombotic treatment group

From: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

 

Nothing

n = 93

UFH

n = 153

UFH + Abcx

n = 44

Abcx

n = 65

Bivalirudin

n = 24

Enoxaparin

n = 18

p

Death

9 (9.6)

10 (6.5)

5 (11.4)

5 (7.7)

2 (8.3)

1 (5.5)

0.4

Cardiac death

8 (8.6)

9 (5.9)

5 (11.4)

4 (6.1)

2 (8.3)

0

0.3

Infarction

1 (1)

3 (1.9)

2 (4.5)

1 (1.5)

3 (12.5)

0

0.04

Def./probable thrombosis

2 (2.1)

7 (4.6)

1 (2.2)

2 (3)

3 (12.5)

0

0.08

BARC >1 bleeding

10 (10.7)

10 (6.5)

3 (6.8)

12 (18.5)

1 (4.2)

2 (11.1)

0.01

BARC >2 bleeding

5 (5.4)

2 (1.3)

0

6 (9.2)

0

1 (5.5)

0.01

Brain hemorrhage

3 (3.2)

0

0

1 (1.5)

0

1 (5.5)

0.1

Revascularization

0

3 (1.9)

1 (2.2)

2 (3)

0

0

0.3

Stroke

1 (1)

0

0

1 (1.5)

0

0

0.7

  1. Abcx abciximab, BARC Bleeding Academic Research Consortium, UFH unfractionated heparin